Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Ryvu Therapeutics's share price for the quarter that ended in Mar. 2026 was €5.01. Ryvu Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 23.12 Mil. Therefore, Ryvu Therapeutics's market cap for the quarter that ended in Mar. 2026 was €115.83 Mil.
Ryvu Therapeutics's quarterly market cap
declined
from Sep. 2025 (€144.26 Mil) to Dec. 2025 (€137.10 Mil) and
declined
from Dec. 2025 (€137.10 Mil) to Mar. 2026 (€115.83 Mil).
Ryvu Therapeutics's annual market cap
declined
from Dec. 2023 (€308.88 Mil) to Dec. 2024 (€202.29 Mil) and
declined
from Dec. 2024 (€202.29 Mil) to Dec. 2025 (€137.10 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Ryvu Therapeutics's Enterprise Value for Today is €78.81 Mil.
Ryvu Therapeutics (STU:9Y4) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Ryvu Therapeutics Market Cap Related Terms
Ryvu Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Ryvu Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:9Y4 vs VRTX, REGN, RVMD: Market Cap Comparison
For the Biotechnology subindustry, Ryvu Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ryvu Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ryvu Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Ryvu Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Ryvu Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ryvu Therapeutics (STU:9Y4) has a Market Cap of €80.06 Mil as of Jul. 27, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Ryvu Therapeutics and its competitors. According to the industry distribution chart, Ryvu Therapeutics ranks #762 out of 1422 companies in the Biotechnology industry, placing it in the top 53.6%.
Is Ryvu Therapeutics' Market Cap too high?
Ryvu Therapeutics' current Market Cap is €80.06 Mil. Based on the distribution chart, Ryvu Therapeutics ranks #762 out of 1422 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ryvu Therapeutics has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ryvu Therapeutics' Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ryvu Therapeutics ranks #762 out of 1422 companies for Market Cap. This places Ryvu Therapeutics in the lower half of its industry. The industry median Market Cap is 110.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 110.94, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Ryvu Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 110.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ryvu Therapeutics's current Market Cap is €80.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ryvu Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ryvu Therapeutics (STU:9Y4) is currently considered Possible Value Trap. The stock's GF Value™ is €10.19, compared to a current price of €3.31 — trading 67.6% below its estimated fair value. The current Market Cap is €80.06 Mil. Ryvu Therapeutics' overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Ryvu Therapeutics (STU:9Y4), the current Market Cap is €80.06 Mil as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ryvu Therapeutics (STU:9Y4) Overvalued in 2026?
Based on GuruFocus' analysis, Ryvu Therapeutics stock appears to be undervalued.
The current stock price of €3.31 is trading 67.6% below its estimated GF Value™ of €10.19.
GuruFocus considers Ryvu Therapeutics to be Possible Value Trap.
Key valuation signals for STU:9Y4:
Market Cap: €80.06 Mil
GF Value™: €10.19 vs. price of €3.31 (67.6% below fair value)
No single metric tells the full story. See the STU:9Y4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
68GF Score
Get the complete analysis for STU:9Y4
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:9Y4 has been successfully added to your 
